TheHun Posted - 6 minutes ago

$PHAR “Recent expansion in Pharming Group by Morgan Stanley. Morgan Stanley, a prominent financial services firm, has recently expanded its investment portfolio by acquiring new holdings in Pharming Group (PHGUF, Financial). On September 30, 2024, the firm purchased 44,161,479 shares of Pharming Group at a price of $0.7547 per share. This significant transaction marks a new position in the biopharmaceutical company, reflecting a strategic move by Morgan Stanley in the healthcare sector.”

OmyLord Posted - 1 day ago

$PHAR Pharming repeated their statement: Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases (e.g. immunology, hematology, respiratory and gastroenterology). Emission is comming! Especially for the analytisch wensdenker alias Triple A

OmyLord Posted - 1 day ago

$PHAR Pharming pre-market: -2.9%, where it fall -2.6% yesterday. The LIC long term losers club said in 2022 when stock price was 1.40: Met het oog op de huidige situatie en het het toekomstperspectief van Pharming zijn wij ervan overtuigd dat het aanhouden van een positie voor de langere termijn een mooi rendement zal opleveren. Wij denken hierbij aan een koers die ruim boven €3,00 zal liggen, oftewel een stijging van meer dan 200% ten opzichte van de huidige koers. HAHAHA That gave them high losses instead.

CatherineBrady Posted - 1 day ago

$PHAR $CRVS $KRRO LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

SeraphineFrost Posted - 3 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $PHAR $CRVS

Addyson_Fuentes Posted - 6 days ago

$PHAR $CRVS MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏

Ruconestor Posted - 1 week ago

$PHAR Professor Kattepis

OmyLord Posted - 1 week ago

$PHAR Pharming down -3.4% Next to the UK ignoring leniolisib, more bad news comming?

Noobnr1 Posted - 1 week ago

$DVAX 🚀🚀🚀🚀🚀🚀 $PFE $PHAR $GILD 💎💎💎

Ruconestor Posted - 2 weeks ago

$PHAR We verhogen de outlook naar $37 We volgen

Ruconestor Posted - 2 weeks ago

$PHAR News ahead? Aquisition rumours??

OmyLord Posted - 2 weeks ago

$PHAR Pharming $PHAR and the UK leniolisib authorisation Bad news for Pharming. UK NICE does NOT recommend leniolisib. Shareholders already paying the price. NICE: Recommendations 1.1 Leniolisib is not recommended, within its marketing authorisation, for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over. There are uncertainties in the economic modelling around how best to model the effect of stopping treatment. Because of the uncertainties in the economic model, it is not possible to determine the most likely cost-effectiveness estimates for leniolisib. So it is not recommended https://www.nice.org.uk/guidance/GID-HST10059/documents/draft-guidance

OmyLord Posted - 2 weeks ago

$PHAR Interesting information about sir klik-plak and the multi-accounts: https://www.iex.nl/forum/post/8238958.aspx Never trusted the situation around ’een van de slechtste beleggers van iex’

OmyLord Posted - 2 weeks ago

$PHAR Interesting information

Ruconestor Posted - 10/28/24

$PHAR Zie IE deMon od de Magere op zijn pikkie getrapt door zn IE maatjes. Pharming gaat terug richting de euro

Thestocktraderhubzee Posted - 10/24/24

WATCHLIST OCT 25 2024 $ARE RBC Capital Downgrades Alexandria Real Estate to Sector Perform, Lowers Price Target to $125 $PHAR HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target $LUMO HC Wainwright & Co. Downgrades Lumos Pharma to Neutral, Lowers Price Target to $4.25 $NEE Guggenheim Maintains Buy on NextEra Energy, Raises Price Target to $92 $GSHD JMP Securities Maintains Market Outperform on Goosehead Insurance, Raises Price Target to $115

auzzy Posted - 10/24/24

$PHAR the conference it tomorrow

Ruconestor Posted - 1 month ago

$PHAR Buy on the dips ey de Mon😉

Ruconestor Posted - 1 month ago

$PHAR Nieuw patent voor pharming Sinds eergisteren gepubliceerd: USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED SYMPTOMS Jul 7, 2022 - Pharming Intellectual Property B.V. The claimed invention relates to treatment of virus-related neurological symptoms, particularly methods for treating such symptoms by administering a complement inhibitor. The types of virus-related neurological symptoms that can be treated according to the invention include extreme fatigue, sensory loss such as loss of taste, cognitive changes, seizures, tremor, and stroke, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified C1 inhibitor. patents.justia.com/assignee/pharming New patent! Monday up up up

Noobnr1 Posted - 1 month ago

$PFE FDA Approval!!! 👏🍾🚀 Hympavzi medecin for hemofille A and B $GILD $DVAX $PHAR $GLPG come on show us also some news 🐇💉💊💎

Ruconestor Posted - 09/27/24

$PHAR Meneer voorheen bekend als de Mon(gool) heeft momenteel lastig op IEX. Het wachten is op de EMEA goedkeuring💪

Ruconestor Posted - 09/26/24

$PHAR Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS) Pharming Group N.V. announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

ms1sd Posted - 08/29/24

$PHAR target SP > $25...let's go!

DougieFreshPicks Posted - 3 months ago

$PHAR ‪It looks good not sure why it does not look right on Finviz but my charts I built look good!!! ‬

Ziebof Posted - 3 months ago

$PHAR Aug. 2, 2024, 06:33 AM In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Pharming Group (PHAR – Research Report), with a price target of $31.00. The company’s shares closed yesterday at $7.63. According to TipRanks, Jones is a 4-star analyst with an average return of 8.3% and a 37.76% success rate. Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Chemomab Therapeutics, and Corbus Pharmaceuticals. Pharming Group has an analyst consensus of Moderate Buy, with a price target consensus of $34.00, a 345.61% upside from current levels. In a report released yesterday (1 Augustus 2024), H.C. Wainwright also reiterated a Buy rating on the stock with a $37.00 price target.

Goofynervous Posted - 07/30/24

$IMNN $ATPC $ISPO $PHAR on the move... Next low float runner TRNR w/major catalyst coming 08/13/2024 see report here >>> https://bestgrowthstocks.com/interactive-strength-inc-nasdaq-trnr-breakout-analysis/

Trader78887 Posted - 07/30/24

$PHAR $NDRA

GambitMentality Posted - 07/30/24

Here are the #StockMarket Pre-Market GAINERS led by $IMNN up 200%, $PCSA up 79%, then $HLIT $PHAR and $ISPO to lead out the TOP 5

JorgeEF Posted - 07/30/24

$PHAR trust 15% up

ClassifiedTrades Posted - 07/30/24

$PHAR $IMNN INVO $QXO NIPG ISPO VVPR CAAR